Navigation Links
Reactivated gene shrinks tumors

more likely to become cancerous, because they will divide uncontrollably even when DNA is damaged.

In this study, the researchers used engineered mice that had the gene for p53 turned off. But, they also included a genetic "switch" that allowed the researchers to turn p53 back on after tumors developed.

Once the switch was activated, p53 appeared in the tumor cells and the majority of the tumors shrank between 40 and 100 percent.

The researchers looked at two different types of cancer-lymphomas and sarcomas. In lymphomas, or cancers of the white blood cells, the cancer cells underwent apoptosis within 1 or 2 days of the p53 reactivation.

In contrast, sarcomas (which affect connective tissues) did not undergo apoptosis but went into a state of senescence, or no growth. Those tumors took longer to shrink but the senescent tumor cells were eventually cleared away.

The researchers are not sure why these two cancers are affected in different ways, but they have started trying to figure it out by identifying the other genes that are activated in each type of tumor when p53 turns back on.

The study also revealed that turning on p53 has no damaging effects in normal cells. The researchers had worried that p53 would kill normal cells because it had never been expressed in those cells.

"This means you can design drugs that restore p53 and you don't have to worry too much about toxic side effects," said Ventura.

Possible therapeutic approaches to turn on p53 in human cancer cells include small molecules that restore mutated p53 proteins to a functional state, as well as gene therapy techniques that introduce a new copy of the p53 gene into tumor cells. One class of potential drugs now under investigation, known as nutlins, acts by interfering with MDM2, an enzyme that keeps p53 levels low.

In follow-up studies, the MIT researchers are looking at other types of cancer, such as epithelial
'"/>

Source:Massachusetts Institute of Technology


Page: 1 2 3

Related biology news :

1. Ultrasounds show mothers drinking shrinks fetal brain
2. Overfishing large sharks impacts entire marine ecosystem, shrinks shellfish supply
3. Pulsating ultrasound enhances gene therapy for tumors
4. A new link between stem cells and tumors
5. Prostate cancer uses Wnt signaling proteins to promote growth of bone tumors
6. Double trouble: Cells with duplicate genomes can trigger tumors
7. Common molecular signature identified in solid tumors
8. Virus chip detects new virus in prostate tumors
9. Macrophage signaling may affect hormone resistance in prostate tumors
10. Common molecular signature identified in solid tumors
11. Vegetables inhibit growth of prostate cancer in mice with human tumors
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Reactivated gene shrinks tumors

(Date:12/14/2009)... HOUSTON -- (Dec. 14, 2009) -- Researchers at Rice ... a single nanoparticle that can be tracked in real ... cells, tags them with a fluorescent dye and kills ... the first examples from a growing field called "theranostics" ... treat diseases in a single procedure. , The research ...
(Date:12/14/2009)... as a clean-burning, renewable fuel that could help wean ... caused by ozone, compared with gasoline, especially in winter, ... , Ozone production from both gasoline and E85, ... percent ethanol, is greater in warm sunny weather than ... because heat and sunlight contribute to ozone formation. But ...
(Date:12/14/2009)... Engineering Society (BMES) have founded a new journal ... CVET is a forum for research on ... The first issue of the new quarterly journal will ... publications at Springer, Annals of Biomedical Engineering ... Cardiovascular Engineering and Technology will present a wide ...
Breaking Biology News(10 mins):Tracking new cancer-killing particles with MRI 2Ethanol-powered vehicles generate more ozone than gas-powered ones 2Ethanol-powered vehicles generate more ozone than gas-powered ones 3Biomedical Engineering Society's new journal to be published by Springer 2Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 1Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 2Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 3Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 4Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 5Prospective Clinical Advantages of Trabecular Metal 28TM 29 Technology Highlighted in Comparative Study 4750 1Prospective Clinical Advantages of Trabecular Metal 28TM 29 Technology Highlighted in Comparative Study 4750 2Prospective Clinical Advantages of Trabecular Metal 28TM 29 Technology Highlighted in Comparative Study 4750 3Prospective Clinical Advantages of Trabecular Metal 28TM 29 Technology Highlighted in Comparative Study 4750 4Prospective Clinical Advantages of Trabecular Metal 28TM 29 Technology Highlighted in Comparative Study 4750 5Vein Condition May Mask Serious Clot Disorder 52152 1Vein Condition May Mask Serious Clot Disorder 52152 2
... plants, human antibodies that could be used to treat ... 2005 American Society for Microbiology Biodefense Research Meeting. , ... is likely to strike at a time and place ... unpredictable nature of such events compels us to develop ...
... before they reach hospital, has the potential to save many ... over a million children die of malaria in Africa. The ... For those who do make it to hospital, half of ... given by injection, is not possible to administer outside hospital, ...
... of breast cancer,patients have an abnormality in a ... along that pathway may be,especially effective for treating ... Texas M. D. Anderson Cancer Center.", , A ... the phosphatidylinositol 3 kinase (PI3K),pathway to breast cancer ...
Other Biology News:Antibodies from plants protect against anthrax 2
(Date:12/14/2009)... THOUSAND OAKS, Calif., Dec. 14 Array ... Inc.(Nasdaq: AMGN ) today announced that they ... rights to Array,s small-molecule glucokinase activator program, including ... clinical trial in patients with Type 2 diabetes. ... agreement, Array will receive an upfront payment of ...
(Date:12/14/2009)... The third edition of ... published by the Infusion Nurses Society (INS), ... extravasation.(1) Anthracyclines are a group of chemotherapy ... have been used in the treatment of various ... ,, According to the INS publication: "In ...
(Date:12/14/2009)... WALTHAM, Mass., Dec. 14 Decision Resources, ... firms for pharmaceutical and healthcare issues, finds that, ... the atrial fibrillation drug market will increase more ... $6.1 billion in 2018 in the United States, ... Japan. ,, The new Pharmacor report entitled ...
(Date:12/11/2009)... 11 Dendreon Corporation (Nasdaq: DNDN ... previously announced public offering have exercised in full ... of common stock at the public offering price ... the option increases the size of the offering ... stock. Dendreon expects to receive net proceeds ...
Breaking Biology Technology:Array BioPharma and Amgen Partner in Type 2 Diabetes 2Array BioPharma and Amgen Partner in Type 2 Diabetes 3Array BioPharma and Amgen Partner in Type 2 Diabetes 4Array BioPharma and Amgen Partner in Type 2 Diabetes 5Array BioPharma and Amgen Partner in Type 2 Diabetes 6Array BioPharma and Amgen Partner in Type 2 Diabetes 7Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3
... Million in 3Q08 -- ... $16.5 Million -- -- ... NEW YORK, Nov. 10 /Xinhua-PRNewswire-FirstCall/ -- American Oriental,Bioengineering, Inc. ... through the development, manufacture and commercialization,of a broad range of ...
... AVIV, Israel, November 10 InspireMD, developers of,the ... MGuard(TM),was successfully implanted in a complex lesion in ... was performed by Dr. Dariusz Dudek and was ... New Approach to Treating Thrombus Containing Lesions (ACS, ...
... ... ... pharmaceuticals company, today announced,that it had successfully closed a third ... developing its unique,CriticalMix delivery technology and matching pipeline of candidate ...
Other Biology Technology:American Oriental Bioengineering Reports Third Quarter 2008 Financial Results 2American Oriental Bioengineering Reports Third Quarter 2008 Financial Results 3American Oriental Bioengineering Reports Third Quarter 2008 Financial Results 4American Oriental Bioengineering Reports Third Quarter 2008 Financial Results 5American Oriental Bioengineering Reports Third Quarter 2008 Financial Results 6American Oriental Bioengineering Reports Third Quarter 2008 Financial Results 7American Oriental Bioengineering Reports Third Quarter 2008 Financial Results 8MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008 2MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008 3MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008 4Critical Pharmaceuticals Raise GBP650K 2Critical Pharmaceuticals Raise GBP650K 3